“MindMed is pioneering the future of brain health with potential groundbreaking treatments, and I am thrilled to join a company dedicated to transforming patient outcomes in an area of immense public health need,” - Stephanie Fagan, newly appointed Chief Corporate Affairs Officer of MindMed We’re excited to welcome Stephanie Fagan to the MindMed team, as Chief Corporate Affairs Officer. With over 20 years of experience as an executive in the healthcare industry, Ms. Fagan will serve as an executive team member, overseeing public affairs and corporate communications.
MindMed
Biotechnology Research
New York, NY 33,027 followers
MindMed is a clinical-stage biopharma company developing novel products to treat brain health disorders
About us
MindMed is a clinical-stage biopharmaceutical company developing novel products to treat brain health disorders, with a particular focus on psychiatry, addiction, pain and neurology. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative drug candidates, with and without acute perceptual effects, targeting the serotonin, dopamine and acetylcholine systems. MindMed trades on the NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED.
- Website
-
http://www.mindmed.co
External link for MindMed
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- New York, NY
- Type
- Public Company
- Founded
- 2019
Locations
-
Primary
One World Trade Center
Suite 8500
New York, NY 10007, US
-
Toronto, Ontario M5H 1A1, CA
Employees at MindMed
Updates
-
1̳9̳5̳0̳-̳1̳9̳6̳0̳ Psychedelic research blossomed to reveal innovative approaches to treatments, showing the potential of psychedelics to enhance emotional insight and facilitate profound psychological breakthroughs. As we build upon this rich history, we're working to shape a brighter future for mental health care, with innovative treatments that offer hope to individuals suffering from mental health issues. #psychedelics #MentalHealth
-
-
Time for the poll results! If you guessed "All of the above", you're correct! GAD can manifest in many ways that might seem unrelated at first. If you're experiencing any of these symptoms, it might be time to reach out to a mental healthcare professional: - Excessive worry - Restlessness - Fatigue - Upset stomach, stomach pains and/or nausea - Difficulty concentrating - Irritability - Muscle tension - Sleep disturbances, like trouble falling or staying asleep Remember, GAD is a common condition and early intervention can significantly improve your quality of life. Don't hesitate to seek professional help if you recognize these signs in yourself or a loved one.
-
-
An exciting day for us at MindMed! We're thrilled to announce the issuance of a new patent covering the pharmaceutical formulation for our MM120 Orally Disintegrating Tablet (ODT). This patent extends our IP protection for MM120 through 2041 and covers the unique properties of our MM120 ODT formulation. Stay tuned for updates as we advance into Phase III! Read the full Press Release here: https://lnkd.in/d26kkmUW
-
According to Psychology Today, 30% of adults in North America experience anxiety, but only a third of them are properly diagnosed. This means nearly 10% of the adult population may have undiagnosed or misdiagnosed anxiety issues. Raising awareness and improving diagnosis is crucial for better mental health care. So, how well do you know GAD? Answer our poll below - and check back next week to find out the answer!
This content isn’t available here
Access this content and more in the LinkedIn app
-
Psychedelic research is moving at an outstanding pace - and sometimes it's hard to keep up! Our CMO, Dan Karlin answers questions such as, "What is FDA breakthrough designation?" and more. Watch the video here: https://lnkd.in/ekYVEVfW
Daniel Karlin, MD: FDA Grants Breakthrough Designation to MM120 for Anxiety
hcplive.com
-
We are thrilled to announce that MindMed has been included in the Russell 2000® Index and the broad-market Russell 3000® Index. “MindMed’s inclusion in the Russell 2000® index marks an important milestone that reflects our commitment to addressing the unmet medical needs for people with brain health disorders." - Robert Barrow, CEO of Mindmed Based on market-capitalization rankings and style attributes, the #Russell3000 Index features the 3,000 largest U.S.-traded stocks. This inclusion means automatic membership in either the large-cap Russell 1000® Index or the small-cap Russell 2000® Index, along with the appropriate growth and value style indexes. Read the full press release here: https://lnkd.in/dH6hWF5J
MindMed to be Included in Russell 2000® and Russell 3000® Indexes
businesswire.com
-
We were honored to have Robert Barrow, our CEO, present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference earlier this morning. In case you missed it, check out the replay of the fireside chat here: https://lnkd.in/d3ERM4zQ
-
-
We’re rethinking brain health, working to unlock the therapeutic potential of psychedelics to meet unmet patient needs. Our investigational treatment (in development) has shown the potential to increase baseline connectivity between brain regions by activating serotonin-2A receptors. What are the potential impacts of increased neuronal connectivity? → Altered perception, behavior, and mood → Intensified thoughts, emotions, and sensory experiences → Creation of new neural pathways (neurogenesis) → Reduced rumination and anxiety Learn more today.
-
-
Check out today’s news release regarding our development program for MM120 in the treatment of generalized anxiety disorder in adults. https://lnkd.in/dstCu2CJ
MindMed Announces Constructive End-of-Phase 2 Meeting with U.S. FDA for MM120 in Generalized Anxiety Disorder (GAD)
ir.mindmed.co